Abacavir/lamivudine combination in the treatment of HIV: A review

Geetha Sivasubramanian, Emmanuel Frempong-Manso, Rodger David MacArthur

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Abacavir has been at the center of research and clinical interest in the last two years. The frequency of the associated abacavir hypersensitivity syndrome has decreased substantially since the introduction of routine testing for the HLA-B*5701 allele; the activity of the drug in HIV-infected persons with HIV RNA values more than 100,000 copies/mL has been questioned; the possible increased risk of myocardial infarction after recent exposure to abacavir has been debated; and the drug has been moved from the "recommended" category to the "alternative" category in several guidelines. Still, the drug remains a useful agent in combination with other drugs, including lamivudine, for the treatment of HIV infection. This review will focus on the pharmacokinetics, activity, side effects, and resistance profile of both abacavir and lamivudine, including a thorough review of all of the recent studies relevant to both drugs.

Original languageEnglish (US)
Pages (from-to)83-94
Number of pages12
JournalTherapeutics and Clinical Risk Management
Volume6
Issue number1
StatePublished - Apr 19 2010

Fingerprint

HIV
drug
Pharmacokinetics
RNA
Pharmaceutical Preparations
Testing
Therapeutics
Lamivudine
HLA-B Antigens
HIV Infections
Hypersensitivity
Alleles
Myocardial Infarction
lamivudine drug combination abacavir
Guidelines
human being
Research
abacavir
Values

Keywords

  • Abacavir
  • HIV
  • Lamivudine

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Cite this

Abacavir/lamivudine combination in the treatment of HIV : A review. / Sivasubramanian, Geetha; Frempong-Manso, Emmanuel; MacArthur, Rodger David.

In: Therapeutics and Clinical Risk Management, Vol. 6, No. 1, 19.04.2010, p. 83-94.

Research output: Contribution to journalReview article

Sivasubramanian, Geetha ; Frempong-Manso, Emmanuel ; MacArthur, Rodger David. / Abacavir/lamivudine combination in the treatment of HIV : A review. In: Therapeutics and Clinical Risk Management. 2010 ; Vol. 6, No. 1. pp. 83-94.
@article{fa7cffa573fe4c5ab82d933638ce8065,
title = "Abacavir/lamivudine combination in the treatment of HIV: A review",
abstract = "Abacavir has been at the center of research and clinical interest in the last two years. The frequency of the associated abacavir hypersensitivity syndrome has decreased substantially since the introduction of routine testing for the HLA-B*5701 allele; the activity of the drug in HIV-infected persons with HIV RNA values more than 100,000 copies/mL has been questioned; the possible increased risk of myocardial infarction after recent exposure to abacavir has been debated; and the drug has been moved from the {"}recommended{"} category to the {"}alternative{"} category in several guidelines. Still, the drug remains a useful agent in combination with other drugs, including lamivudine, for the treatment of HIV infection. This review will focus on the pharmacokinetics, activity, side effects, and resistance profile of both abacavir and lamivudine, including a thorough review of all of the recent studies relevant to both drugs.",
keywords = "Abacavir, HIV, Lamivudine",
author = "Geetha Sivasubramanian and Emmanuel Frempong-Manso and MacArthur, {Rodger David}",
year = "2010",
month = "4",
day = "19",
language = "English (US)",
volume = "6",
pages = "83--94",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Abacavir/lamivudine combination in the treatment of HIV

T2 - A review

AU - Sivasubramanian, Geetha

AU - Frempong-Manso, Emmanuel

AU - MacArthur, Rodger David

PY - 2010/4/19

Y1 - 2010/4/19

N2 - Abacavir has been at the center of research and clinical interest in the last two years. The frequency of the associated abacavir hypersensitivity syndrome has decreased substantially since the introduction of routine testing for the HLA-B*5701 allele; the activity of the drug in HIV-infected persons with HIV RNA values more than 100,000 copies/mL has been questioned; the possible increased risk of myocardial infarction after recent exposure to abacavir has been debated; and the drug has been moved from the "recommended" category to the "alternative" category in several guidelines. Still, the drug remains a useful agent in combination with other drugs, including lamivudine, for the treatment of HIV infection. This review will focus on the pharmacokinetics, activity, side effects, and resistance profile of both abacavir and lamivudine, including a thorough review of all of the recent studies relevant to both drugs.

AB - Abacavir has been at the center of research and clinical interest in the last two years. The frequency of the associated abacavir hypersensitivity syndrome has decreased substantially since the introduction of routine testing for the HLA-B*5701 allele; the activity of the drug in HIV-infected persons with HIV RNA values more than 100,000 copies/mL has been questioned; the possible increased risk of myocardial infarction after recent exposure to abacavir has been debated; and the drug has been moved from the "recommended" category to the "alternative" category in several guidelines. Still, the drug remains a useful agent in combination with other drugs, including lamivudine, for the treatment of HIV infection. This review will focus on the pharmacokinetics, activity, side effects, and resistance profile of both abacavir and lamivudine, including a thorough review of all of the recent studies relevant to both drugs.

KW - Abacavir

KW - HIV

KW - Lamivudine

UR - http://www.scopus.com/inward/record.url?scp=77950814004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950814004&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:77950814004

VL - 6

SP - 83

EP - 94

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -